In its latest announcement, Bao Minh Securities Joint Stock Company (code: BMS) has registered to purchase 3 million DBD shares of Binh Dinh Pharmaceutical – Medical Equipment Joint Stock Company (Bidiphar) from September 12 to October 11, 2024, to restructure its investment portfolio.
Prior to this transaction, BMS did not hold any DBD shares. If the transaction is successful, this securities company will own 3.21% of Binh Dinh Pharmaceutical’s capital. In terms of relationship, BMS is an organization related to Mr. Phan Tan Thu – Member of Bidiphar’s Board of Directors.
In the market, DBD shares have been range-bound recently. Currently, the market price stands at VND 40,800/share. Based on this price, it is estimated that BMS will have to spend approximately VND 122 billion to increase its ownership in DBD.
According to our understanding, Bidiphar was established in 1979 and is one of the largest pharmaceutical companies in Central Vietnam. The company officially transitioned to operating as a joint-stock company in 2014.
Bidiphar is known for being a pioneer in researching and producing cancer treatment medications , injectable antibiotics, and infusion solutions. The company also boasts 7 production facilities equipped with advanced technology that meet GMP-WHO standards.
To date, Bidiphar’s cancer treatment portfolio includes dozens of products used to treat various types of cancer. This product line is utilized in most specialized hospitals and those with oncology departments, such as K Hospital, Ho Chi Minh City Oncology Hospital, Cho Ray Hospital, and Bach Mai Hospital, among others.
Regarding its investment plan for 2024, Bidiphar expects to disburse more than VND 842 billion; nearly VND 108 billion of which will be allocated for investing in the purchase, upgrading, and repair of equipment for the factory at 498 Nguyen Thai Hoc. Over VND 734 billion will be invested in ongoing projects, including: Nhon Hoi Cancer Hospital (VND 84 billion); Sterile Small Volume Production Plant (nearly VND 624 billion); and Bidiphar Office Building (VND 16.4 billion)…
For new investment projects, Bidiphar has a new investment item for the Non-Betalactam OSD Factory, with a total investment capital of VND 850 billion, dedicated to the solid oral dosage form production line.
The factory, which is built in the Nhon Hoi Economic Zone (Quy Nhon city, Binh Dinh province), meets GMP-EU standards and has a capacity of 1.3 billion products/year (equivalent to 100 tons/year). It is scheduled to commence construction in 2025.
In terms of business performance in the first half of 2024, Bidiphar recorded approximately VND 817 billion in net revenue, a slight increase of 3% compared to the same period last year. After-tax profit reached approximately VND 140 billion, a minor decrease of 2%. Compared to the plan approved by the 2024 Annual General Meeting of Shareholders, DBD achieved 41% of the revenue target and nearly 52% of the profit target for the year.
